XBRU:NYXH (Belgium)
Business Description
Nyxoah SA
Rue Edouard Belin 12, Mont-Saint Guibert, BEL, 1435
Compare
Compare
Traded in other countries / regions
NYXH.Belgium
•
5YI.Germany
•
NYXH.USA
Description
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. Nyxoah's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 10.04 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.09 | |||||
| Debt-to-EBITDA | -1.64 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 5.27 | |||||
| Beneish M-Score | 4.53 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -30.5 | |||||
| 3-Year EPS without NRI Growth Rate | -38.7 | |||||
| 3-Year FCF Growth Rate | -58.4 | |||||
| 3-Year Book Growth Rate | 125.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 69.66 | |||||
| 9-Day RSI | 62.15 | |||||
| 14-Day RSI | 55.92 | |||||
| 6-1 Month Momentum % | -53.24 | |||||
| 12-1 Month Momentum % | -67.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.24 | |||||
| Quick Ratio | 7.21 | |||||
| Cash Ratio | 7.02 | |||||
| Days Inventory | 181.04 | |||||
| Days Sales Outstanding | 120.2 | |||||
| Days Payable | 1638.25 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 60.94 | |||||
| Operating Margin % | -919.87 | |||||
| Net Margin % | -732.98 | |||||
| ROE % | -9.09 | |||||
| ROA % | -7.64 | |||||
| ROIC % | -43.54 | |||||
| ROC (Joel Greenblatt) % | -164.71 | |||||
| ROCE % | -6.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 166.45 | |||||
| PB Ratio | 1.93 | |||||
| Price-to-Tangible-Book | 2.52 | |||||
| EV-to-EBIT | -18.46 | |||||
| EV-to-EBITDA | -20.78 | |||||
| EV-to-Revenue | 97.55 | |||||
| EV-to-Forward-Revenue | 31.68 | |||||
| EV-to-FCF | -8.8 | |||||
| Price-to-Net-Current-Asset-Value | 2.71 | |||||
| Price-to-Net-Cash | 2.82 | |||||
| Earnings Yield (Greenblatt) % | -5.42 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 1.595 | ||
| EPS (TTM) (€) | -1.044 | ||
| Beta | 0 | ||
| Volatility % | 36.58 | ||
| 14-Day RSI | 55.92 | ||
| 14-Day ATR (€) | 0.528547 | ||
| 20-Day SMA (€) | 9.992 | ||
| 12-1 Month Momentum % | -67.46 | ||
| 52-Week Range (€) | 7.57 - 27.45 | ||
| Shares Outstanding (Mil) | 25.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nyxoah SA Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||